Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is poised for success in the coming years as they continue to expand their portfolio and offerings in the radiopharmaceutical space. With new and potentially lucrative partnerships in the works, such as with GE for Flyrcado, the company is positioning itself for increased revenue and growth. Additionally, their recent acquisitions, including LNTH-2501 and the diagnostic agent Pylarify, are expected to contribute significantly in the future. All of these factors, coupled with the company's strong financials, make Lantheus an attractive investment opportunity with potential for long-term success.

Bears say

Lantheus Holdings is showing positive revenue and EPS performance, but with a decline in pricing for their key product Pylarify, which could impact future revenue growth. There are potential growth opportunities in the pipeline, such as FDA approval for LNTH-2501, but it is contingent on resolving manufacturing issues. The current multiple of 14.5x P/E does not reflect the potential for future growth and the company's potential receipt of TPT status from the FDA could level the reimbursement playing field, but it remains uncertain at this point.

Lantheus Holdings (LNTH) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 7 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.